Osprey Medical Inc. PRESERV Clinical Trial Update
10 Jun 2013
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MINNEAPOLIS & MELBOURNE, Australia--(BUSINESS WIRE)--Osprey Medical Inc. (ASX: OSP) today announced updates in its PRESERV Clinical Trial, with Dr. Richard Heuser enrolling in May 2013 the first US patients in the PRESERV Clinical Trial at St. Luke’s Medical Center in Phoenix, Arizona. Dr. Heuser is an internationally recognized cardiologist, inventor, educator and author and is one of the early pioneers of the angioplasty procedure. In addition to St. Luke’s Medical Center, twelve additional hospitals have Institutional Review Board (IRB) and contract approval and are actively screening patients for trial enrollment. An additional 25 hospitals are actively pursuing IRB and contract approval.
Help employers find you! Check out all the jobs and post your resume.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.